Loading…
247rxpill.in was cited for introducing unapproved and misbranded opioid and benzodiazepine drugs into interstate commerce through its website, violating sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA emphasized that these controlled substance violations posed significant public health risks given the ongoing opioid epidemic and the potential for benzodiazepine abuse, particularly when combined with other drugs. The agency noted that unapproved drugs lack safety and effectiveness assurances and may be contaminated or otherwise unsafe.